UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $54.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 289.89% from the stock's previous close.

Separately, Oppenheimer dropped their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an "outperform" rating for the company in a research note on Friday, March 15th.

UroGen Pharma Price Performance

NASDAQ URGN traded down $0.45 during trading hours on Monday, hitting $13.85. 397,986 shares of the company's stock traded hands, compared to its average volume of 326,589. UroGen Pharma has a 52-week low of $8.69 and a 52-week high of $24.13. The company has a market capitalization of $324.78 million, a PE ratio of -3.71 and a beta of 1.09. The firm's 50-day moving average is $15.22 and its 200-day moving average is $14.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analyst estimates of $22.30 million. Equities research analysts predict that UroGen Pharma will post -3.59 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 12,000 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the transaction, the insider now directly owns 139,437 shares in the company, valued at $1,959,089.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 11.13% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its position in UroGen Pharma by 361.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company's stock valued at $54,000 after buying an additional 2,801 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at about $53,000. SG Americas Securities LLC acquired a new position in shares of UroGen Pharma during the fourth quarter worth about $131,000. Federated Hermes Inc. purchased a new stake in shares of UroGen Pharma during the third quarter worth approximately $184,000. Finally, Sierra Summit Advisors LLC acquired a new stake in UroGen Pharma in the fourth quarter valued at approximately $218,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.